Eye health issues have attracted much attention, how to protect the "vision" with innovation

Help people see a brighter world

Ms. Liu, 56, has a hardware factory. She had only 100 degrees myopia, but gradually realized that her vision began to decline, and the number of myopia also deepened. This has a great impact on Ms. Liu's daily life, because she starts to see the details on the hardware parts. After going to the hospital for treatment, Ms. Liu was diagnosed with cataract.

At the same time, Ms. Liu originally had a high degree of astigmatism of -1.75D (175 degrees). In this case, even if artificial crystal implantation surgery was underwent, ordinary multi-focus trice crystals could not meet the needs of postoperative astigmatism correction.

Fortunately, in July this year, Ms. Liu obtained a 0.8 vision by implanted a new type of three -focus artificial crystal body.

New choice

Ms. Liu is also the first group of artificial crystal in the country in the country. As the attending doctor of Ms. Liu, Yao Ke, the Ophthalmology Hospital of Zhejiang University of Zhejiang University of Medicine, Zhejiang University Medical College, introduced that according to epidemiological survey data, my country 41.8%of patients with cataract patients have corneal astigmatism greater than 1D (the degree of astigmatism is represented by refractiveness, and the 100 degrees of refractive records are recorded as 1D). Under normal circumstances, astigmatism below 0.5D has little effect on vision. When astigmatism is higher than 0.5D, it will affect the patient's vision. The main symptoms of patients' astigmatism include: blurred vision, squinting, dizziness and headache, which not only affects visual quality, but also the quality of life will also be affected.

The surgical source of cataract surgery and the pre -gittic of patients with cataract patients have always been the focus of doctors. Clinically, the technology of artificial crystals has also developed from the past monocular and double -focus to the current three focus, which better solve the natural visual experience of mid -range visual insufficient visual and realized continuous vision. However, there is still a need for demand for cataract patients with astigmatism.

Until July this year, a new generation of three -focus artificial lens brought more choices to patients with cataracts. After this artificial crystal was approved to be listed, in early July, the first batch of implant surgery was performed in Zhejiang, Guangdong, Shandong, Liaoning, Beijing, Shanghai, and Chongqing. The three -focus artificial crystal of the astigmatism correction function is officially landed in China and is applied to the clinic. The new artificial crystal fills the blank of the current three focus artificial crystals in astigmatism correction, while bringing better visual quality to patients, while also corrected astigmatism and achieved thorough mirror.

And the company that promotes this innovative technology is the leader of the global ophthalmology field.

Innovation leads "vision"

Just in May this year, Elkang ushered in a milestone in the 75th anniversary of the global establishment. In May 1947, the two pharmacist Robert Alexander and William Conne jointly founded Elkon to start producing special medicines in Vosburrt in Texas.

Robert Alexander (right) and William Conner (left)

To this day, this small pharmacy, which was originally focused on sterile ophthalmic products, has developed into the world's largest professional company and medical device professional company. Visual experience.

For a long time, Elkang has regarded innovation as a proud tradition, and believes that innovation is the vitality of the company's biological industry. Elkan launched the first Droptainer® eye drop bottle in 1953, and launched Focus® in 1990 -the first soft contact lenses specifically used for regular replacement. IOL) is also the first product developed specially developed for IOL. These innovations have kept Elkon's forefront of the industry.

Innovation is inseparable from R & D, and Elkon's R & D investment has been in the leading position in the market. In 2021, more than 600 million US dollars were used for research and development, and super strong R & D innovation capabilities allowed technology and products to quickly improve. Globally, Elkang has more than 1,400 R & D personnel is constantly working hard to discover new technologies and methods, and more than 100 are effective research projects.

In 1995, Irkang established a Chinese company, and now it has entered China that is near the "year of standing". Based on the Chinese local market, Elkan has deeply insight into consumer demand, continuously introduces innovative technology to provide new choices for Chinese consumers.

Erkang has two major product lines: ophthalmology and vision health care. In the ophthalmological surgery business, the combination of Elkon's surgical products includes technology and equipment for cataracts, retina, and refractive surgery, and advanced technology artificial lens for the treatment of cataracts and refractives (such as old flowers and astigmatism).

The artificial crystals of Erkang have accounted for 31%of the global market share in 2017. The product series has single -focus astigmatism correction, old vision correction, informal artificial crystals, and multi -focus artificial crystals with astigmatism correction.

Among them, the launch of the Panoptix® tri -focus artificial crystal was the first and only three -focus crystal approved by the US Food and Drug Administration (FDA) at that time. Listing.

This year, Elkon has been upgraded again in the field of artificial crystals. It has launched the only three -focus artificial crystal with astigmatism correction function in China. The scattered correction range has further expanded the applicable crowd of three -focus artificial crystals, and benefited more cataract patients. In addition to the innovation in the field of surgery, in terms of vision health, Elkon is also one of the world's leading contact lenses and lens care products manufacturers. The product portfolio provides a wide range of daily use, reusable use and color contact lenses, and comprehensive eye health product portfolios, including products for dry eye, contact lenses care and eye allergies, as well as eye vitamin and vitamin and vitamin and Red and swollen relieving agent.

Unlike traditional medical products, although contact lenses are medical equipment, the brand is "dealing" with a large number of terminal consumers. Based on the keen insights on consumer demand, Elkon has continued to innovate in the technology of contact lenses, bringing consumers a continuously improved wearing experience.

For the poor visual effects, the lack of consistent and clear vision, the comfort cannot last for a whole day, it is not easy to wear, and the price is higher than the ideal price, such as contact lenses such as the ideal price. Provide new choices for consumers who are busy and do not want to be dragged by glasses.

Light Che ™ daily throwing contact lenses experience scene

Light Che ™ daily throw is the first application of Aerkang Patent Innovation Technology SmartSurface ™ Smart Run ™ technology contact lenses products, providing users who need long -term wearing to provide long -term moisturizing and best visual experience. Verofilcon's new -generation silicon hydrogel material used in this product makes it achieve high oxygen volume to meet corneal oxygen demand and better care for eye health. SmartSurface ™ Smart Run ™ technology is a lens surface treatment technology based on layered hydration technology, which can make the lens surface water content of 80%, bring lasting moist and comfortable touch, allow consumers , Clear vision and longer comfortable feelings.

At the same time, another highlight of the light Che ™ daily throwing is that on the basis of ensuring the soft and humidity of the lens, it can still be realized when wearing the shape, not soft collapse, and more convenient operation. In addition, light Che ™ daily throws are also a type of anti -UV products certified by international standardization organizations, which can resist ultraviolet rays to a certain extent.

Through precise insight into consumers' needs and innovative technology research and development, Elkon has always occupied a higher share in the contact lens market.

Innovation is the driving force for enterprises to develop in the long run. For Elkan, who has been focusing on ophthalmology for 75 years, "helps people see a brighter world" never changed. At the same time, Elkon is also seeking new opportunities to serve the rapid development of the Chinese market to meet more eye care needs.

Zhang Quanzhi, President of Elkan China, said: "Eye Health, as an important part of the" Healthy China 2030 "plan, has attracted great attention from society. As the leader of the industry, Elkon has 75 years of experience in the world. Continuously bring the internationally -leading ophthalmology equipment and treatment solutions to Chinese patients, and through cooperation with local institutions and enterprises, to strengthen the availability of products to patients, to bring a better visual experience to the vast number of Chinese patients and consumers , Help accelerate the achievement of the 'healthy China', help people see a better world, improve the quality of life, and promote the healthy and sustainable development of the industry. "

Author: Ma Meng

Edit: Wang Xiaoyi

Operation editor: Wang Lin

- END -